Neutralizing Capacity of Monoclonal and Polyclonal Anti-Natalizumab Antibodies: The Immune Response to Antibody Therapeutics Preferentially Targets the Antigen-Binding Site

J Allergy Clin Immunol. 2017 Mar;139(3):1035-1037.e6. doi: 10.1016/j.jaci.2016.09.014. Epub 2016 Oct 4.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / immunology
  • Antibodies, Neutralizing / chemistry*
  • Antibodies, Neutralizing / immunology*
  • Binding Sites
  • Humans
  • Immunologic Factors / immunology*
  • Multiple Sclerosis, Relapsing-Remitting
  • Natalizumab / immunology*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Immunologic Factors
  • Natalizumab